TEVA PHARMACEUTICAL INDUSTRIES LTD Stockholders Equity

• TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +47.2% in Stockholders Equity from 2024 to 2025.
• This data is from TEVA PHARMACEUTICAL INDUSTRIES LTD's annual report (Form 10-K), filed with the SEC on February 3, 2026.
• XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2018: $18.62 billion | Q2 2018: $17.94 billion | Q3 2018: $17.73 billion | Q1 2019: $14.73 billion | Q2 2019: $14.12 billion | Q3 2019: $13.79 billion | Q1 2020: $13.53 billion | Q2 2020: $13.85 billion | Q3 2020: $9.59 billion | Q1 2021: $10.00 billion | Q2 2021: $10.32 billion | Q3 2021: $10.47 billion | Q1 2022: $9.34 billion | Q2 2022: $9.04 billion | Q3 2022: $8.77 billion | Q1 2023: $7.86 billion | Q2 2023: $7.05 billion | Q3 2023: $6.93 billion | Q1 2024: $7.28 billion | Q2 2024: $6.36 billion | Q3 2024: $6.07 billion | Q1 2025: $6.26 billion | Q2 2025: $6.83 billion | Q3 2025: $7.25 billion.
• Over the full 18 years of available data (2008 to 2025), TEVA PHARMACEUTICAL INDUSTRIES LTD's Stockholders Equity has declined by 51.7%.
• Historical annual values: Fiscal year 2025: $7.91 billion | Fiscal year 2024: $5.37 billion | Fiscal year 2023: $7.51 billion | Fiscal year 2022: $7.80 billion | Fiscal year 2021: $10.28 billion | Fiscal year 2020: $10.03 billion | Fiscal year 2019: $13.97 billion | Fiscal year 2018: $14.71 billion | Fiscal year 2017: $17.36 billion | Fiscal year 2016: $33.34 billion | Fiscal year 2015: $29.77 billion | Fiscal year 2014: $23.31 billion | Fiscal year 2013: $22.57 billion | Fiscal year 2012: $22.77 billion | Fiscal year 2011: $22.20 billion | Fiscal year 2010: $21.95 billion | Fiscal year 2009: $19.22 billion | Fiscal year 2008: $16.38 billion.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026